TABLE 1.

Comparison of baseline characteristics between dicycloplatin-sensitive and dicycloplatin-resistant patients.

Baseline characteristic	Sensitive (n = 9)	Resistant (n = 7)	p value	All patients (n = 16)
Age, median (range), years	66 (61–79)	63 (51–72)	0.210	66 (51–79)
Smoking history, no. (%)			0.633
Yes	4 (44.4)	2 (28.6)		6 (37.5)
No	5 (55.5)	5 (71.4)		10 (62.5)
Drinking history, no. (%)			0.596
Yes	2 (44.4)	3 (42.9)		6 (37.5)
No	7 (55.5)	4 (57.1)		10 (62.5)
Tumor stage at diagnosis, no. (%)			1
II	1 (11.1)	0 (0.0)		1 (6.3)
IV	8 (88.8)	7 (100.0)		15 (93.8)
Gleason sum at diagnosis, no. (%)			1
≤7	6 (66.6)	4 (57.1)		10 (62.5)
≥8	3 (33.3)	3 (42.9)		6 (37.5)
Prior treatment for PCa, no. (%)
Surgery	2 (22.2)	1 (14.3)	1	3 (18.8)
Radiotherapy	1 (11.1)	2 (28.6)	0.4	3 (18.8)
Chemotherapy	3 (33.3)	5 (71.4)	0.157	10 (62.5)
Endocrine therapy	2 (22.2)	7 (100.0)	0.003	9 (56.3)
Pretreatment PSA level, median (range), ng/ml	87.6 (9.9–775.6)	79.3 (2.9–800)	0.837	86.0 (2.9–800)
Pretreatment-free PSA level, median (range), ng/ml	14.0 (0.5–48.6)	10.8 (0.9–29.8)	0.681	11.2 (0.5–48.6)

PSA, prostate-specific antigen. p values are based on Fisher’ exact test and Mann–Whitney U test for categorical and continuous parameters, respectively.